• Company
• Optimal doses of Effient and Brilinta different for Koreans
• by Eo, Yun-Ho Jul 22, 2021 05:53am

• Policy
• Onivyde reimb. to be expanded to 2nd-line pancreatic cancer
• by Lee, Hye-Kyung Jul 22, 2021 05:53am

• Policy
• The administration monitoring cycle of Samsca is changed
• by Kim, Jung-Ju Jul 22, 2021 05:53am

• Company
• Celltrion's Regkirona was approved for EUA in Indonesia
• by Kim, Jin-Gu Jul 22, 2021 05:52am

• Company
• Why Keytruda’s smile wavers after passing CDRC deliberation
• by Eo, Yun-Ho Jul 21, 2021 05:52am

• Company
• Antibiotic sales are decreasing due to prolonged COVID-19
• by Chon, Seung-Hyun Jul 21, 2021 05:51am

• Company
• Harvoni’s growth spurt despite Hep C market downturn
• by Nho, Byung Chul Jul 21, 2021 05:51am

• Policy
• GSK & SK Bio also stopped supplying TD vaccines
• by Lee, Tak-Sun Jul 21, 2021 05:51am

• Company
• Domestic Rx sales are showing strength in H1
• by An, Kyung-Jin Jul 21, 2021 05:51am

• Company
• Patent ruling changes NOAC market…Eliquis surpasses Xarelto
• by Kim, Jin-Gu Jul 20, 2021 05:47am